Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GSK plc
  6. News
  7. Summary
    GSK   GB00BN7SWP63

GSK PLC

(GSK)
  Report
Delayed London Stock Exchange  -  11:35:14 2023-01-27 am EST
1410.00 GBX   +0.34%
01/27UK earnings, trading statements calendar - next 7 days
AN
01/26UK earnings, trading statements calendar - next 7 days
AN
01/25UK earnings, trading statements calendar - next 7 days
AN
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Statement: Zantac (ranitidine) litigation

12/07/2022 | 02:12am EST

• MDL Court has dismissed all cases alleging the five remaining cancers in the MDL
• Scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer
• GSK will continue to defend itself vigorously, including against all claims brought at the state level in the U.S.

In response to yesterday's court ruling in the Zantac federal Multi-District Litigation (MDL) in the U.S., GSK plc (LSE/NYSE: GSK) today issued the following statement:

GSK welcomes yesterday's ruling by the MDL Court. Following the 12 epidemiological studies conducted looking at human data regarding the use of ranitidine, the scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer. Yesterday's ruling reflects the state of that science and ensured that unreliable and litigation-driven science did not enter the federal courtroom.

In excluding plaintiffs' epidemiological evidence and expert testimony based on their deficiencies and unreliability, the Court has dismissed all MDL cases alleging the five remaining cancers in the MDL (liver, bladder, pancreatic, esophageal, and stomach). GSK will continue to defend itself vigorously, including against all claims brought at the state level.

Further information regarding the litigation can be found in GSK's 11 August 2022 and 16 August 2022 statements, and in its third quarter results press release issued on 2 November 2022. These are available on www.gsk.com.

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com/company

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the Company's Annual Report on Form 20-F for 2021, GSK's Q3 Results for 2022 and any impacts of the COVID-19 pandemic.

Attachments

Disclaimer

GSK plc published this content on 07 December 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 December 2022 07:11:01 UTC.


ę Publicnow 2022
All news about GSK PLC
01/27UK earnings, trading statements calendar - next 7 days
AN
01/26UK earnings, trading statements calendar - next 7 days
AN
01/25UK earnings, trading statements calendar - next 7 days
AN
01/25GSK : Barclays reiterates its Neutral rating
MD
01/24Pharma Stocks Weigh Down European Equities in Tuesday Trading
MT
01/24Europe's revenue growth expected to slow to a crawl in Q4
RE
01/24UK's FTSE 100 slips ahead of business activity data
RE
01/23Bayer Chairman Faces Criticism From Investor for Lack of Initiative, WirtschaftsWoche R..
DJ
01/19GSK : JP Morgan reaffirms its Sell rating
MD
01/18Factbox-Moderna data puts the spotlight on RSV vaccines under development
RE
More news
Analyst Recommendations on GSK PLC
More recommendations
Financials
Sales 2022 29 105 M 36 036 M 36 036 M
Net income 2022 6 197 M 7 673 M 7 673 M
Net Debt 2022 14 371 M 17 793 M 17 793 M
P/E ratio 2022 8,75x
Yield 2022 4,32%
Capitalization 57 260 M 70 897 M 70 897 M
EV / Sales 2022 2,46x
EV / Sales 2023 2,41x
Nbr of Employees 90 096
Free-Float 93,7%
Chart GSK PLC
Duration : Period :
GSK plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GSK PLC
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 22
Last Close Price 1 410,00 GBX
Average target price 1 694,98 GBX
Spread / Average Target 20,2%
EPS Revisions
Managers and Directors
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Jon Ellis VP & Head-Technology Business Development
Tony Wood Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
GSK PLC-1.92%70 897
JOHNSON & JOHNSON-4.77%439 835
ELI LILLY AND COMPANY-4.87%325 056
NOVO NORDISK A/S1.06%312 363
ROCHE HOLDING AG-0.40%277 685
MERCK & CO., INC.-5.02%267 180